The Glycated Albumin Assay Market, estimated at USD 666.9 Mn in 2025, is expected to exhibit a CAGR of 8.1% and reach USD 1,148.1 Mn by 2032.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
Key players in the market are focusing on adoption of inorganic growth strategies such as partnerships and collaborations, in order to strengthen their market presence in the global glycated albumin assay market which is expected to drive the market growth over the forecast period. For instance, in August 2025, Precision Diabetes, Inc., a bioscience company and DxGen Corp., which is a Point-Of-Care (POC) diagnostics company situated in U.S., announced that they have entered in an exclusive agreement in the U.S. to launch Epithod AutoDx, a fully-automatic point-of-care (POC) analyzer that measures a comprehensive profile of diabetes tests.
Global Glycated albumin assay market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown that was imposed in several countries such as India, China, Brazil, and others problems were faced with regards to the transportation of drugs from one place to another.
The COVID-19 had a positive impact on the global glycated albumin assay market, owing to its diagnostic application in the COVID-19-pandemic. For instance, in April 2025, a report published on MDPI, which is an open source scientific journal, described the use of glycated albumin assay to predict the progression of coronavirus disease from mild to severe disease in Korean patients with type 2 diabetes.
Global glycated albumin assay market: Key Developments
In September 2025, Boehringer Ingelheim, a German based company which is a pharmaceutical company, acquires Abexxa Biologics, a biopharmaceutical company, to further expand Boehringer Ingelheim’s research efforts in cancer immunology and novel immunotherapeutic approaches.
In December 2025, Labcorp, a leading global life sciences company, announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, U.S., expanding the company’s global central laboratory capabilities.
In December 2025, Asahi Kasei Pharma Corporation, which is a research-based, health care innovator company, announced that they have received the U.S. Food and Drug Administration (FDA) approval to manufacture and sell Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg in Japan for treatment of the fungal infections of aspergillosis, mucormycosis, and cryptococcosis.